Insulin Therapy for Pre-Hyperglycemic Beta-Cell Endoplasmic Reticulum Crowding

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Absood, Afaf ^a   Gandomani, Benjamin ^a   Zaki, Anthony ^a   Nasta, Vlad ^a   Michail, Andrew ^b   Habib, Peter M W ^b   Hodish, Israel ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN DETEMIR; PROINSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GLUCOSE TOLERANCE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SYNTHESIS; INSULIN TREATMENT; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; TRANSGENIC MOUSE;

ANIMALS; BLOTTING, WESTERN; ENDOPLASMIC RETICULUM; IMMUNOHISTOCHEMISTRY; INSULIN; ISLETS OF LANGERHANS; MICE; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84873599585     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054351     Document Type: Article

References (54)

1. Li Y, Xu W, Liao Z, Yao B, Chen X, et al. (2004) Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 27: 2597-2602.
2. Ryan EA, Imes S, Wallace C, (2004) Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 27: 1028-1032.
3. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, et al. (2003) Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26: 2231-2237.
4. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, et al. (2008) Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 31: 1927-1932.
5. Weng J, Li Y, Xu W, Shi L, Zhang Q, et al. (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371: 1753-1760.
6. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G, (2000) Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol 37: 125-129.
7. The writing team of the DCCT (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 128: 517-523.
8. Panero F, Novelli G, Zucco C, Fornengo P, Perotto M, et al. (2009) Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 32: 301-305.
9. Manzella D, Carbonella M, Ragno E, Passariello N, Grella R, et al. (2002) Relationship between autonomic cardiac activity, beta-cell function, anthropometrics and metabolic indices in type II diabetics. Clin Endocrinol (Oxf) 57: 259-264.
10. Manzella D, Ragno E, Abbatecola AM, Grella R, Paolisso G, (2003) Residual C-peptide secretion and endothelial function in patients with Type II diabetes. Clin Sci (Lond) 105: 113-118.
11. Abdul-Ghani MA, Tripathy D, DeFronzo RA, (2006) Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29: 1130-1139.
12. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, et al. (1985) Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res Suppl 15: 41-46.
13. Karve A, Hayward RA, (2010) Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults. Diabetes care 33: 2355-2359.
14. Jonas JC, Bensellam M, Duprez J, Elouil H, Guiot Y, et al. (2009) Glucose regulation of islet stress responses and beta-cell failure in type 2 diabetes. Diabetes Obes Metab 11Suppl 4: 65-81.
15. Leahy JL, Bonner-Weir S, Weir GC, (1988) Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 81: 1407-1414.
16. Chick WL, Like AA, (1970) Studies in the diabetic mutant mouse. 3. Physiological factors associated with alterations in beta cell proliferation. Diabetologia 6: 243-251.
17. Flax H, Matthews DR, Levy JC, Coppack SW, Turner RC, (1991) No glucotoxicity after 53 hours of 6.0 mmol/l hyperglycaemia in normal man. Diabetologia 34: 570-575.
18. Kluth O, Mirhashemi F, Scherneck S, Kaiser D, Kluge R, et al. (2011) Dissociation of lipotoxicity and glucotoxicity in a mouse model of obesity associated diabetes: role of forkhead box O1 (FOXO1) in glucose-induced beta cell failure. Diabetologia 54: 605-616.
19. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB, (2008) Is glycemic control improving in U.S. adults? Diabetes Care 31: 81-86.
20. Like AA, Chick WL, (1970) Studies in the diabetic mutant mouse. II. Electron microscopy of pancreatic islets. Diabetologia 6: 216-242.
21. Marchetti P, Bugliani M, Lupi R, Marselli L, Masini M, et al. (2007) The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 50: 2486-2494.
22. Izumi T, Yokota-Hashimoto H, Zhao S, Wang J, Halban PA, et al. (2003) Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. Diabetes 52: 409-416.
23. Sachdeva MM, Claiborn KC, Khoo C, Yang J, Groff DN, et al. (2009) Pdx1 (MODY4) regulates pancreatic beta cell susceptibility to ER stress. Proc Natl Acad Sci U S A 106: 19090-19095.
24. Gupta S, McGrath B, Cavener DR, (2010) PERK (EIF2AK3) Regulates Proinsulin Trafficking and Quality Control in the Secretory Pathway. Diabetes 59: 1937-1947.
25. Hatanaka M, Tanabe K, Yanai A, Ohta Y, Kondo M, et al. (2011) Wolfram syndrome 1 gene (WFS1) product localizes to secretory granules and determines granule acidification in pancreatic beta-cells. Hum Mol Genet 20: 1274-1284.
26. Florez JC, (2007) The new type 2 diabetes gene TCF7L2. Curr Opin Clin Nutr Metab Care 10: 391-396.
27. Stancakova A, Pihlajamaki J, Kuusisto J, Stefan N, Fritsche A, et al. (2008) Single-nucleotide polymorphism rs7754840 of CDKAL1 is associated with impaired insulin secretion in nondiabetic offspring of type 2 diabetic subjects and in a large sample of men with normal glucose tolerance. J Clin Endocrinol Metab 93: 1924-1930.
28. Sandefur CI, Schnell S, (2011) A model of threshold behavior reveals rescue mechanisms of bystander proteins in conformational diseases. Biophys J 100: 1864-1873.
29. Despa F, (2009) Dilation of the endoplasmic reticulum in beta cells due to molecular overcrowding? Kinetic simulations of extension limits and consequences on proinsulin synthesis. Biophys Chem 140: 115-121.
30. Hodish I, Absood A, Liu L, Liu M, Haataja L, et al. (2011) In vivo misfolding of proinsulin below the threshold of frank diabetes. Diabetes 60: 2092-2101.
31. Junger E, Herberg L, Jeruschke K, Leiter EH, (2002) The diabetes-prone NZO/Hl strain. II. Pancreatic immunopathology. Lab Invest 82: 843-853.
32. Yoshioka M, Kayo T, Ikeda T, Koizumi A, (1997) A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 46: 887-894.
33. Hara M, Wang X, Kawamura T, Bindokas VP, Dizon RF, et al. (2003) Transgenic mice with green fluorescent protein-labeled pancreatic beta-cells. Am J Physiol Endocrinol Metab 284: E177-183.
34. Leiter EH, (1989) The genetics of diabetes susceptibility in mice. FASEB J 3: 2231-2241.
35. Hodish I, Liu M, Rajpal G, Larkin D, Holz RW, et al. (2010) Misfolded proinsulin affects bystander proinsulin in neonatal diabetes. J Biol Chem 285: 685-694.
36. Like AA, Chick WL, (1970) Studies in the diabetic mutant mouse. I. Light microscopy and radioautography of pancreatic islets. Diabetologia 6: 207-215.
37. Han BG, Hao CM, Tchekneva EE, Wang YY, Lee CA, et al. (2008) Markers of glycemic control in the mouse: comparisons of 6-h- and overnight-fasted blood glucoses to Hb A1c. Am J Physiol Endocrinol Metab 295: E981-986.
38. Rosenthal EB, Bashan E, Herman WH, Hodish I (2011) The Effort Required to Achieve and Maintain Optimal Glycemic Control. The Journal of Diabetes and its Complications. In Press.
39. Magami Y, Azuma T, Inokuchi H, Moriyasu F, Kawai K, et al. (2002) Heterogeneous cell renewal of pancreas in mice: ((3)H)-thymidine autoradiographic investigation. Pancreas 24: 153-160.
40. Porcellati F, Bolli GB, Fanelli CG, (2011) Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther 13Suppl 1: S15-24.
41. Leroux L, Desbois P, Lamotte L, Duvillie B, Cordonnier N, et al. (2001) Compensatory responses in mice carrying a null mutation for Ins1 or Ins2. Diabetes 50Suppl 1: S150-153.
42. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D, (2000) Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2: 326-332.
43. Freychet P, (1974) The interactions of proinsulin with insulin receptors on the plasma membrane of the liver. J Clin Invest 54: 1020-1031.
44. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, et al. (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289: 76-79.
45. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, et al. (2005) beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 90: 493-500.
46. Garcia-Estevez DA, Araujo-Vilar D, Saavedra-Gonzalez A, Fiestras-Janeiro G, Cabezas-Cerrato J, (2002) Glucose metabolism in lean patients with mild type 2 diabetes mellitus: evidence for insulin-sensitive and insulin-resistant variants. Metabolism 51: 1047-1052.
47. Boffetta P, McLerran D, Chen Y, Inoue M, Sinha R, et al. (2011) Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. PLoS One 6: e19930.
48. Staiger H, Machicao F, Fritsche A, Haring HU, (2009) Pathomechanisms of type 2 diabetes genes. Endocr Rev 30: 557-585.
49. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England journal of medicine 346: 393-403.
50. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443.
51. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367: 319-328.
52. Bache I, Jorgensen KH, Buschard K, (1997) Failure of high-dose insulin treatment to increase beta-cell insulin content in diabetic non obese diabetic (NOD) mice. Diabetes Res Clin Pract 37: 9-14.
53. Kautz S, van Burck L, Schuster M, Wolf E, Wanke R, et al. (2012) Early insulin therapy prevents beta cell loss in a mouse model for permanent neonatal diabetes (Munich Ins2(C95S)). Diabetologia 55: 382-391.
54. Li HQ, Wang BP, Deng XL, Zhang JY, Wang YB, et al. (2011) Insulin improves beta-cell function in glucose-intolerant rat models induced by feeding a high-fat diet. Metabolism 60: 1566-1574.